Kymera Therapeutics, Inc. $KYMR Shares Sold by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. lessened its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 19.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 276,455 shares of the company's stock after selling 66,243 shares during the quarter. Alyeska Investment Group L.P. owned approximately 0.33% of Kymera Therapeutics worth $31,701,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of KYMR. Baker BROS. Advisors LP grew its position in Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company's stock valued at $673,620,000 after acquiring an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Kymera Therapeutics by 17.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company's stock worth $581,610,000 after purchasing an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company's stock valued at $487,685,000 after purchasing an additional 845,922 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company's stock valued at $479,258,000 after purchasing an additional 1,061,957 shares during the period. Finally, BlackRock Inc. acquired a new position in shares of Kymera Therapeutics in the second quarter valued at approximately $635,067,000.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR opened at $118.15 on Monday. Kymera Therapeutics, Inc. has a 12 month low of $39.84 and a 12 month high of $130.05. The firm has a market capitalization of $9.82 billion, a P/E ratio of -36.47 and a beta of 1.95. The company's fifty day moving average price is $112.78 and its 200 day moving average price is $93.71.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The company had revenue of $65.00 million for the quarter, compared to analyst estimates of $32.78 million. During the same quarter last year, the company posted ($0.95) earnings per share. The business's quarterly revenue was up 465.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -3.78 EPS for the current year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 80,000 shares of the firm's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the transaction, the chief executive officer directly owned 666,568 shares of the company's stock, valued at approximately $76,848,624.72. This trade represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Bruce N. Jacobs sold 77,109 shares of the firm's stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total value of $8,864,450.64. Following the transaction, the chief financial officer directly owned 244,883 shares in the company, valued at approximately $28,151,749.68. This represents a 23.95% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 3,587,629 shares of company stock worth $386,183,782. 15.98% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Oppenheimer reaffirmed an "outperform" rating and set a $125.00 price objective on shares of Kymera Therapeutics in a research report on Wednesday, August 5th. Citigroup reissued a "buy" rating on shares of Kymera Therapeutics in a research note on Thursday, August 6th. Truist Financial upped their price target on Kymera Therapeutics from $116.00 to $136.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Morgan Stanley reaffirmed an "overweight" rating and issued a $135.00 price target on shares of Kymera Therapeutics in a research report on Thursday, August 6th. Finally, Loop Capital set a $97.00 price objective on Kymera Therapeutics in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Kymera Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $127.17.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source